Article contents
The economics of schizophrenia care in Europe: the Epsilon study
Published online by Cambridge University Press: 07 August 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorials
- Information
- Copyright
- Copyright © Cambridge University Press 2002
References
REFERENCES
Becker, T., Knapp, M.R.J., Knudson, H.C., Schene, A., Tansella, M. & Vasquez-Barquero, J.L. (2000). Aims, outcome measures, study sites and patient sample, British Journal of Psychiatry 177, Suppl. no. 39, 1–7.CrossRefGoogle Scholar
Becker, T., Gaite, L., Knapp, M., Knudsen, H.C., Leese, M., Ruggeri, M., Schene, A., Tansella, M., Thornicroft, G., Vázquez-Barquero, J.L., Welcher, B. & Van Wijngaarden, B. (2002). The iceberg tip and the rest. Mental health care for people with schizophrenia in five European centres. Epidemiologia e Psichiatria Sociale 11, 6–11.CrossRefGoogle ScholarPubMed
Beecham, J.K. & Knapp, M.R.J. (1992). Costing psychiatric interventions. In Measuring Mental Health Needs (ed. Thornicroft, G., Brewin, C. and Wing, J.K.). Gaskell: London.Google Scholar
Bonizzato, P., Bisoffi, G., Amaddeo, F., Chisholm, D. & Tansella, M. (2000). Community-based mental health care: to what extent are service costs associated with clinical, social and service history variables? Psychological Medicine 30, 1205–1215.CrossRefGoogle ScholarPubMed
Burns, T., Knapp, M.R.J., Catty, J., Healey, A.T., Henderson, J., Watt, H. & Wright, C. (2001). Home treatment for mental health problems: a systematic review. Health Technology Assessment 5, 15.CrossRefGoogle ScholarPubMed
Chisholm, D., Knapp, M.R.J., Knudsen, H.C., Amaddeo, F., Gaite, L., van Wijngaarden, B. & the EPSILON Study Group (2000). Client Socio-demographic and Service Receipt Inventory – EU version: development of an instrument for international research. British Journal of Psychiatry 177, Suppl. no. 39, 28–33.CrossRefGoogle Scholar
Essock, S.M., Frisman, L.K., Covell, N.H. & Hargreaves, W.A. (2000). Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Archives of Psychiatry 57, 987–994.CrossRefGoogle ScholarPubMed
Evers, S.M. & Ament, A.J. (1995). Costs of schizophrenia in the Netherlands. Schizophrenia Bulletin 21, 141–153.CrossRefGoogle ScholarPubMed
Hamilton, S.H., Revicki, D.A., Edgell, E.T., Genduso, L.A. & Tollefson, G. (1999). Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 15, 469–480.CrossRefGoogle ScholarPubMed
Haro, J.M., Salvador-Carulla, L., Cabases, J., Madoz, V. & Vazquez-Barquero, J.L. (1998). Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. British Journal of Psychiatry 173, 334–340.CrossRefGoogle ScholarPubMed
Harris, E.C. & Barraclough, B. (1998). Excess mortality of mental disorder. British Journal of Psychiatry 173, 11–53.CrossRefGoogle ScholarPubMed
Healey, A.T., Knapp, M.R.J., Astin, J., Beecham, J.K., Kemp, R., Kirov, G. & David, A. (1998). Cost-effectiveness evaluation of compliance therapy for people with psychosis. British Journal of Psychiatry 172, 420–424.CrossRefGoogle ScholarPubMed
Johnson, S., Salvador-Carulla, L. & The EPCAT Group (2000). Description and classification of mental health services: an European perspective. European Psychiatry 13, 333–341.CrossRefGoogle Scholar
Joy, C.B., Adams, C.E. & Lawrie, S.M. (2001). Haloperidol versus placebo for schizophrenia (Cochrane Review). Cochrane Library, Issue 3.Google Scholar
Knapp, M.R.J. (1997). Cost of schizophrenia. British Journal of Psychiatry 171, 509–518.CrossRefGoogle Scholar
Knapp, M.R.J., Chisholm, D., Leese, M., Amaddeo, F., Schene, A., Thornicroft, G., Vasquez-Barquero, J.L., Knudson, H.C., Becker, T. & the EPSILON Study Group (in press). Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. Acta Psychiatrica Scandinavica.Google Scholar
McCrone, P., Thornicroft, G., Phelan, M.Holloway, F., Wykes, T. & Johnson, S. (1998). Utilisation and costs of community mental health services. British Journal of Psychiatry 173, 391–398.CrossRefGoogle ScholarPubMed
Rosenheck, R., Cramer, J., Allan, E., Erdos, J., Frisman, L.K., Xu, W., Thomas, J., Henderson, W. & Charney, D. (1999). Cost effectiveness of clozapine in patients with high and low levels of hospital use. Archives of General Psychiatry 56, 565–572.CrossRefGoogle ScholarPubMed
Thornicroft, G. & Tansella, M. (1999). The Mental Health Matrix. A Manual to Improve Services. Cambridge University Press: Cambridge.CrossRefGoogle Scholar
Thornley, B., Adams, C.E. & Awad, G. (2001). Chlorpromazine versus placebo for schizophrenia (Cochrane Review). Cochrane Library, Issue 1.Google Scholar
World Health Organisation (2001). Mental Health: New Understanding, New Hope. WHO: Geneva.Google Scholar
Xiong, W., Phillips, M.R., Hu, X., Wang, R., Dai, Q., Kleinman, J. & Kleinman, A. (1994). Family-based intervention for schizophrenic patients in China: a randomised controlled trial. British Journal of Psychiatry 165, 239–247.CrossRefGoogle Scholar
You have
Access
- 8
- Cited by